TARIX ORPHAN, LLC.;UNIVERSITY OF IOWA RESEARCH FOUNDATION
发明人:
MARK CHAPLEAU,RASNA SABHARWAL,RICHARD FRANKLIN
申请号：
BR112015026286
公开号：
BR112015026286A2
申请日:
2014.04.18
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
Patent Summary: "Angiotensins in Muscular Dystrophy". The present invention relates, among others, to methods for treating muscular dystrophy, including administering to an individual suffering or susceptible to muscular dystrophy an angiotensin (1-7) peptide. The present invention is based in part on the unexpected discovery that administration of an angiotensin (1-7) peptide in an animal model of muscular dystrophy reduces fibrosis, restores locomotor activity, and restores sympathovagal balance. which are characteristic symptoms in patients suffering from muscular dystrophy. Thus, the present invention provides a more effective new therapy for muscular dystrophy. in some embodiments, an angiotensin (1-7) peptide includes the natural amino acid sequence of angiotensin (1-7), asp1-arg2-val3-tyr4-ile5-his6-pro-7 (seqid no: 1). In some embodiments, the angiotensin peptide (1-7) is a functional equivalent of sequence: 1. in some embodiments, the linear peptide has an amino acid sequence equal to asp1-arg2-val3-ser4-h'is5-cys7 (seq id no: 2). in some embodiments, the cyclic peptide is a 4,7-cyclized angiotensin (1-7).resumo patente de invenção: "angiotensinas na distrofia muscular". a presente invenção refere-se, entre outros, a métodos, para tratar distrofia muscular, incluindo administrar a um indivíduo que sofre ou é suscetível a uma distrofia muscular um peptídeo angiotensina (1-7). a presente invenção fundamenta-se, em parte, na descoberta inesperada de que a administração de um peptídeo angiotensina (1-7) em um modelo animal de distrofia muscular reduz a fibrose, recupera a atividade locomotora e restaura o equilíbrio simpático-vagal, os quais são sintomas característicos em pacientes que sofrem de distrofia muscular. assim, a presente invenção provê uma nova terapia mais eficaz para distrofia muscular. em algumas modalidades, um peptídeo angiotensina (1-7) inclui a sequência natural de aminoácidos da angiotensina (1-7), asp1-arg2-val3-tyr4-ile5-his6-pro-7 (seq i
